Until recently, genomics was a «read-only» science. But scientists led by Rory Johnson at the University of Bern and the Centre for Genomic Regulation in Barcelona, have now developed a tool for quick and easy deletion of DNA in living cells.
This software will boost efforts to understand the vast regions of non-coding DNA, or «Dark Matter», in our DNA and may lead to discovery of new disease-causing genes and potential new drugs.
Genomics is the field of research studying how our «genome», or entire DNA sequence, specifies a human being, and how errors in this sequence give rise to diseases. Genomics was recently a «read-only» endeavour: researchers used powerful technology to read genomes’ sequence and their regulatory layers. However until recently, there was no way to edit or delete DNA for either basic research objectives, or for potential therapeutic interventions.
Just a few years ago, this outlook changed dramatically with the discovery of a revolutionary technique for editing genomes: «CRISPR-Cas9». CRISPR-Cas9 is a molecular tool composed of two simple components: a molecular barcode, called «sgRNA», which is designed by the researcher to recognise one precise location in the genome; and a protein, Cas9, that binds to a structured loop in the sgRNA. By introducing these two units, researchers may perform a wide range of operations on specific pieces of genomic DNA, from introducing small mutations, to regulating gene activity, to tagging it with small sequences. Until recently most studies employing CRISPR-Cas9 were aimed at silencing protein-coding genes, the best-studied part of our genome.
However our genome consists of 99% of DNA that does not encode any protein. Often described as the «Dark Matter» of the genome, this «non-coding DNA» is recognised to be crucially important for understanding all aspects of human biology, including disease and evolution. Until recently, the experimental tools to study this have not been available.
Researchers studying non-coding DNA have been particularly excited about the discovery of CRISPR-Cas9 because it can be used as a powerful tool for studying non-coding DNA for the first time. Prof Rory Johnson, at the Centre for Genomic Regulation (CRG) in Barcelona, Spain and now at the National Center of Competence in Research (NCCR) RNA & Disease and Department of Clinical Research of the University of Bern, recently created a tool based on CRISPR-Cas9, called «DECKO», which can be used to delete any desired piece of non-coding DNA. The unique advantage of DECKO is that it uses two individual sgRNAs, acting like two molecular scissors that snip out a piece of DNA. Numerous researchers worldwide have adopted this approach, attracted by its simplicity and effectiveness.
While working on DECKO, Johnson and colleagues realised that no software was available for designing the pairs of sgRNAs that are required, meaning that designing deletion experiments was time-consuming. To overcome this, Johnson recruited Masters student Carlos Pulido to design a software pipeline called CRISPETa. They were assisted by a team of laboratory researchers including co-first authors of this paper Estel Aparicio and Carme Arnan, who carried out experiments to validate the software’s predictions.
CRISPETa is a powerful and flexible solution for designing CRISPR deletion experiments. The user tells CRISPETa what region they wish to delete, and the software returns a set of optimised pairs of sgRNAs that can directly be used by experimental researchers. One of the key features is that it can create designs at high scales, with future screening experiments in mind. Importantly, CRISPETa is designed for use by non-experts, and is available in a user friendly website, making CRISPR deletion available to the widest possible number of scientific and biomedical researchers.
In the CRISPETa study, the researchers also introduce a new version of DECKO, which is cheaper and faster than the previous one. The researchers showed that CRISPETa designs efficiently delete their desired targets in human cells. Most importantly, in those regions that give rise to RNA molecules, the researchers showed that the RNA molecules also carry the deletion.
CRISPETa will be useful for scientific researchers, from even the most modest experimental laboratory. These users may, for example, delete a suspected functional region of non-coding DNA, and test the outcome on cellular or molecular activity. This software will also be potentially valuable for groups aiming to utilise CRISPR deletion for therapeutic purposes, by for example, deleting a region of non-coding DNA that is suspected to cause a disease state. Therefore CRISPETa will be a valuable tool for the hundreds of research teams worldwide who are using CRISPR deletion.
«We hope that this new software tool will allow the greatest possible number of researchers to harness the power of CRISPR deletion in their research», says Carlos Pulido, the student who wrote the CRISPETa software.
«Ultimately, we expect that CRISPR deletion and other genome engineering tools to lead to a revolution in our ability to understand the genomic basis of disease, particularly in the 99% of DNA that does not encode proteins. Apart from being used as a basic research tool, CRISPR may even be used in the future as a powerful therapeutic to reverse disease-causing mutations», adds Rory Johnson.
Receive an email update when we add a new GENOMIC MEDICINE article.
The Latest on: Genomic medicine
via Google News
The Latest on: Genomic medicine
- Global Precision Medicine Software Market 2020-2024 | Evolving Opportunities with F. Hoffmann-La Roche Ltd. and Fabric Genomics Inc. | Technavioon January 26, 2020 at 7:27 am
The global precision software market is poised to grow by USD 882.65 million during 2020-2024, progressing at a CAGR of 11%.
- Genetic Sequencing Study Identifies 102 Genes Associated With Autismon January 24, 2020 at 7:18 am
In the largest genetic sequencing study of autism spectrum disorder (ASD ... Director of the Seaver Autism Center for Research and Treatment at Icahn School of Medicine at Mount Sinai. For the study ...
- Exome sequencing in newborns with congenital deafness as a model for genomic newborn screening: the Baby Beyond Hearing projecton January 23, 2020 at 5:21 pm
Genet Med. 2016;18:221–230. Berg JS, Agrawal PB, Bailey DB, et al. Newborn sequencing in genomic medicine and public health. Pediatrics. 2017;139:e20162252. Howard HC, Knoppers BM, Cornel MC, Wright ...
- Unravelling arthropod genomic diversity over 500 million years of evolutionon January 23, 2020 at 8:21 am
the i5k has grown into a broad community of scientists using genomics to study insects and other arthropods in many different contexts from fundamental animal biology, to effects on ecology and the ...
- PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Serviceon January 23, 2020 at 6:46 am
PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for ...
- State-backed Genomics Medicine Ireland reports almost €38m losson January 23, 2020 at 4:42 am
In the same year it received $400m in funding, Genomics Medicine Ireland racked up a pre-tax loss. Genomics Medicine Ireland (GMI) has posted its latest accounts, showing the Chinese-owned company ...
- Genome Medical Adds Population Genomics Offering to Enable Increased Access for Individuals Nationwideon January 23, 2020 at 4:00 am
/PRNewswire/ -- Genome Medical, a leader in telegenomics-based clinical care, today announced that it has expanded its services to enable ...
- Genomics in healthcare: How systems are using the data and whether there is a cause for concernon January 22, 2020 at 1:35 pm
Several health systems across the country have entered into high profile partnerships in the past year to incorporate genomics into their patient information, while others that got an early start have ...
- Deloitte, Rady Children's Institute for Genomic Medicine Announce Project to Accelerate Medical Sample Delivery Via Unmanned Aircraft Systemson January 21, 2020 at 4:00 am
SAN DIEGO, Jan. 21, 2020 /PRNewswire/ -- Because every minute counts when children's lives are at stake, Deloitte and Rady Children's Institute for Genomic Medicine (RCIGM) are exploring an innovative ...
via Bing News